Biden’s Drug-Pricing Expansion Plan, Part 2

The Biden administration’s proposal to expand the Bayh-Dole march-in framework to include price as a factor in determining that a drug isn’t accessible to the public could change collaboration agreements between universities and biotech companies. But the effort is inconsistent with the legislative intent of the framework, according to Joe Allen, executive director of the Bayh-Dole Coalition. He joins Bloomberg Intelligence analysts Duane Wright and Tish Walker on this episode of the Votes & Verdicts podcast to discuss why price shouldn’t be a factor for march-in rights, and the implications for federally supported research and development if its is.See omnystudio.com/listener for privacy information.